Patent Grant
9238102
The present invention in one aspect concerns a low profile actuator assembly. More particularly the actuator of the present invention utilizes a polymeric actuator configured to generate a large linear displacement over an area in response to a change in an ionic concentration of pH of an electrolyte that is in contact with the polymeric actuator, and the use of a porous electrode separator material in such a device. The invention has particular utility in connection with administration of therapeutic liquids and will be described in connection with such utility, although other utilities are contemplated.
In another aspect the invention concerns a low profile actuator assembly of the above type and a power supply that powers the actuator to displace in one or more linear steps over a time period.
In yet another embodiment the present invention concerns a low profile and volumetrically efficient medication delivery device configured to be placed on the body of a patient during fluid delivery to the patient. More particularly the present invention incorporates a low profile area actuator assembly that causes fluid delivery by displacing a collapsible reservoir in response to receiving a current or charge input from a power supply.
In still another aspect, the invention concerns a method for improving the efficiency of caregiver-controlled administration of low or high potency therapeutic liquids and potentially dangerous medications to a patient in a healthcare facility.
Actuators are devices that generate displacements or force for various applications. These can take on many forms such as motors, air cylinders, hydraulic cylinders, and electromagnetic solenoids to name a few. These actuators are utilized for many different applications and have been in use for decades.
More recently there have been attempts at developing applications for actuators that require small size and “low profile”. By low profile, we mean that the actuator must operate over an area but be spatially constrained in thickness and/or length. This can be quite challenging in the actuator art. An example of such an application is an IV pump that is to be worn by a patient. To avoid discomfort and embarrassment the patient would prefer that such a pump be very thin so as to not be particularly noticeable under clothing or even swim suits.
Conventional actuators do not meet the full need for such an application. There is a need for thinner and lower profile actuators that still meet high performance actuation requirements such as a generation of high forces and displacements. Furthermore the state of the art polymer actuators do not include a separator material to isolate and create distinct ionic or pH boundaries of the electrolyte at the anode or cathode side of the electrodes. This eliminates comingling of the ionic or pH regions, the addition of the separator material substantially increases the response, accuracy, time and volume changes of the actuator material as well as improving the range of electrode materials and configurations of the cathode and anode electrodes within the device.
Patients have need of pumped medication in a variety of settings. Most pumps such as IV pumps are relatively bulky and usually only suitable at a bedside in a managed care environment such as a hospital. More recently medications have been delivered by more portable pumps that may be fastened to the body. Such pumps are more convenient than the larger IV pumps but still suffer from tradeoffs such as limitations on the amount of medication that may be delivered. Moreover, wearing a pump on the body can be quite uncomfortable. There is a need to improve upon these pumps in terms of their comfort and their ability to deliver larger volumes of medication.
Also, critical high potency medications such as Schedule II pain therapeutics are often administered to patients at healthcare facilities. Schedule II pain medications are particularly important for patients having undergone surgeries or having conditions involving acute pain. In such a situation a doctor writes an order or prescription for treatment of the patient. The order is filled or verified by the facility pharmacy and may need to be renewed every 48 to 96 hours. The order can then be dispensed by an automated cabinet system to a caregiver (e.g., a nurse) as required by the patient.
Insufficient or delayed pain therapy may impair a patient's ability to heal and leave the healthcare facility. What is needed is a new process that addresses these issues while simplifying the process of administering the medication.
The present invention, in one aspect, provides a polymeric actuator assembly comprising: a housing; a carrier having an upper surface within the housing; a plurality of discrete polymeric actuators disposed in an area arrangement across the upper surface; an electrolyte contained in the housing and in contact with the plurality of discrete polymeric actuators; and an apparatus for changing the pH in the electrolyte, wherein each discrete polymeric actuator has a volume that expands in response to the change in pH, and each discrete polymeric actuator is geometrically constrained to cause the expansion to be predominantly in a direction that is directed away from the upper surface.
The present invention also provides, in another aspect, a polymeric actuator assembly comprising: a housing; a carrier having an upper surface and a plurality of wells formed in the carrier, each well opening onto the upper surface; a plurality of polymeric actuators each having a volume that is partially contained in a corresponding one of the wells; an electrolyte solution contained within the housing and in contact with the plurality of polymeric actuators; and an apparatus for modifying the pH within the electrolyte solution.
In yet another aspect, the present invention provides a polymeric actuator assembly comprising: a housing; a polymeric actuator within the housing; a first electrode in contact with the electrolyte; a first electrolyte in contact with the polymeric actuator and the first electrode; a second electrode; a second electrode in contact with the second electrode; and a porous separator configured to separate the first electrolyte from the second electrolyte, wherein the first electrolyte is configured to change in pH in response to current passing between the first electrode to the second electrode, and the polymeric actuator is configured to change volume in response to the change in pH.
The present invention, in another aspect also provides an actuator system comprising: a housing; a polymeric actuator having a volume disposed within the housing; an electrolyte within the housing and in contact with the polymeric actuator; an electrode set within the housing and configured to modulate an ion concentration or pH of the electrolyte in response to charge being passed through the electrode set; and a power supply configured to:
Also provided by the present invention is a actuator system comprising: a housing; a polymeric actuator having a volume disposed within the housing; an electrolyte within the housing and in contact with the polymeric actuator; an electrode set within the housing and configured to modulate an ion concentration or pH of the electrolyte in response to charge being passed through the electrode set; and a power supply configured to:
The present invention further provides an actuator system comprising: a polymeric actuator having a volume; an electrolyte in contact with a polymeric actuator; an electrode set configured to modulate an ion concentration or pH of the electrolyte in response to charge being passed through the electrode set; and a power supply configured to programmably pass charge through the electrode such that the polymeric actuator alternates between relatively short periods of rapid expansion each followed by a relatively longer period with reduced expansion.
Additionally, the present invention provides a method of controlling an expansion of a polymeric actuator comprising: providing a housing containing a polymeric actuator, an electrolyte in contact with polymeric actuator, and an electrode set configured to modulate ion concentration or pH within the electrolyte in response to current being passed through the electrode set, the polymeric actuator having a volume that is responsive to the change in ion concentration or pH; passing a first forward bias charge through the electrode set that is sufficient to change the volume to a second volume; and passing a reverse bias charge through the electrode set that is of smaller magnitude than the forward bias charge and that is sufficient to reduce a rate of change of the volume.
The invention also provides a low profile medication delivery device comprising: a chassis having a first pocket and a second pocket; an actuator assembly overlaying a collapsible reservoir disposed within the first pocket; and electronics disposed within the second pocket and coupled to the actuator assembly, the actuator assembly configured to expand and compress the collapsible reservoir in response to current being passed through the actuator assembly.
In yet another aspect, the present invention provides a method of providing therapeutic liquid device comprising: providing a liquid delivery device comprising: a housing configured to be mounted to a patient body; a reservoir within the housing; a fluid delivery device coupled to the reservoir and configured to deliver fluid to the patient; and a controller having a memory device; selecting a medication type and concentration based upon a particular class of patient conditions; filling the reservoir with the type and concentration of the medication; and storing information on the memory device that defines parameters that govern operation of the fluid delivery device pursuant to safety and efficacy of administration specific to the medication type and concentration.
The invention also provides a therapeutic liquid delivery device comprising: a housing configured to be mounted to a patient body; a reservoir within the housing containing a type of medication having a concentration; a fluid delivery device coupled to the reservoir and configured to delivery fluid to the patient; a controller having a memory device storing information including:
The present invention also provides a method of administering a therapeutic fluid comprising: providing a liquid delivery device to a health care facility inventory, the liquid delivery device including:
The invention also provides an article of manufacture for providing a therapeutic liquid comprising a liquid device comprising: a housing configured to be mounted to a patient body; a reservoir within the housing; a fluid delivery device coupled to the reservoir and configured to delivery fluid to the patient; a user interface; and a controller having a computer readable storage medium having computer readable program code disposed therein for storing information on the memory device that defines parameters that govern operation of the fluid delivery device pursuant to safety and efficacy of administration specific to the medication type and concentration.
In addition, the invention provides an article of manufacture for delivering a therapeutic liquid comprising: a housing configured to be mounted to a patient body; a reservoir within the housing containing a medication; a fluid delivery device coupled to the reservoir and configured to delivery fluid to the patient; a controller having a computer readable storage medium having computer readable program code disposed therein for reading information defining parameters received from a filling and programming facility that are specific to the medication type and concentration; receive inputs from the user interface; and operate the fluid delivery device to administer the medication to the patient pursuant to the parameters.
In yet another embodiment, the invention provides an article of manufacture for administering a therapeutic fluid comprising: a liquid delivery device, the liquid delivery device including: a housing configured to be mounted to a patient body; a reservoir within the housing containing a medication having a type and concentration; a fluid delivery device coupled to the reservoir and configured to deliver fluid to the patient; a user interface; and a controller having computer readable storage medium having computer readable program code for storing information defining parameters that govern operation of the fluid delivery device according to safety and efficacy of administration of the medication type and concentration; the controller configured to: read the information defining the parameters; receive inputs from the user interface; and operate the fluid delivery device to administer the medication to the patient pursuant to the parameters; based on a physician order, a caregiver retrieving the liquid delivery device from inventory.
In still yet another embodiment of the invention, the therapeutic liquid delivery device of the present invention is paired with a patient monitoring device such as, for example, a pulse oximeter, a blood CO2 sensor, a respiration rate sensor; a blood pressure monitor, or a glucose monitor, or the like, with feedback to the liquid delivery device controller to adjust, alarm or stop the pump if the patient is showing signs of overmedication. The feedback also could be used to adjust the pump if the patient is showing signs of undermedication.
Further features and advantages of the present invention will be seen from the following detailed description, taken into conjunction with the attached drawings, in which like numerals depict like parts, and wherein,
In the following description directional or geometric terms such as “upper”, “lower”, and “side” are used solely with reference to the orientation of the Figures depicted in the drawings. These are not to imply or be limited to a direction with respect to a gravitational reference frame but are utilized to distinguish directions relative to each other. Because components of the present invention can be positioned in a number of different orientations, the directional terminology is used for purposes of illustration and is in no way limiting. It is to be understood that other embodiments may be utilized and structural or logical changes may be made without departing from the scope of the present invention.
Details in the various embodiments such as how current or wiring is routed to electrodes from power supplies are left out for illustrative simplicity since various methods of such routing is known in the art. The term “electrolyte” refers to and includes all aqueous, non-aqueous, polymer and solid electrolytes, including those that are generally well known in the art. The term “electrodes” refer to anodes and cathodes commonly used in electrochemical systems that are made of materials well known in the art such as metals, carbons, graphenes, oxides or conducting polymers or combinations of these. The term “separator” refers to any nano, micro or macro porous material that allows targeted ions to move through or across it faster than surrounding ion containing media. The term “ion” refers to ions and ion species as well as anion, cation, electrons and protons, and concentration values of these. The term “housing” refers to the exterior portion of the device which may be fabricated from flexible material, rigid material, elastic materials, non elastic materials or a combination of these such as rubbers, silicone, polyurethane, metalized polymer films and other plastics or polymers known in the art. The housing is configured to allow movement and expansion of the internal parts as well as allowing for filling device with electrolyte, acting as a container and barrier to stop any electrolyte leakage or evaporation, allowing electrodes to make electrical contact with power source as well as to enter and exit the housing, if needed, and also the ability to vent any unwanted gas generation, if needed.
The foregoing refers to polymeric actuators. In an exemplary embodiment these polymer actuators are formed from ion or pH responsive epoxy polymer Hydrogel based polymers. Examples of such polymers are described in commonly owned WIPO patent application WO 2008079440A2, Entitled ‘SUPER ELASTIC EPDXY HYDROGEL”, filed on Jul. 10, 2007 and published on Jul. 3, 2008. Other polymer actuator examples may contain polymers which have ionic functional groups, such as carboxylic acid, phosphoric acid, sulfonic acid, primary amine, secondary amine, tertiary amine, and ammonium, acrylic acid, methacrylic acid, vinylacetic acid, maleic acid, meta kurir yl oxy ethylphosphoric acid, vinylsulfonic acid, styrene sulfonic acid, vinylpyridine, vinylaniline, vinylimidazole, aminoethyl acrylate, methylamino ethyl acrylate, dimethylamino ethyl acrylate, ethylamino ethyl acrylate, ethyl methylamino ethyl acrylate, diethylamino ethyl acrylate, aminoethyl methacrylate, methylamino ethyl methacrylate, dimethylaminoethyl methacrylate, ethylamino ethyl methacrylate, ethyl methylamino ethyl methacrylate, diethylamino ethyl methacrylate, aminopropyl acrylate, methylaminopropyl acrylate, dimethylamino propylacrylate, ethylaminopropyl acrylate, ethyl methylaminopropyl acrylate, diethylamino propylacrylate, aminopropyl methacrylate, methylaminopropyl methacrylate, dimethylaminopropyl methacrylate, ethylaminopropyl methacrylate, ethyl methylaminopropyl methacrylate, polymers, such as diethylamino propyl methacrylate, dimethylaminoethyl acrylamide, dimethylaminopropylacrylamide, and alpha kurir yl oxy ethyl trimethylammonium salts, are reported to be of use but these examples are for reference and not intended to limit the scope or use of the invention.
An exemplary embodiment of a system 100 according to the present invention is schematically depicted with respect to
Actuator assembly 105 includes a polymeric actuator 102 and an associated electrode set 104 including top electrode 106 and bottom electrode 108. The electrode set 104 and the polymeric actuator 102 are contained within housing 110. Contained within housing 110 is an electrolyte solution 112U and 112L that immerses the electrode set 104 and actuator 102. Separating electrode 108 from electrode 106 is a porous separator membrane 114. The electrolyte includes an upper electrolyte portion 112U that is in fluidic and electrical contact with upper electrode 106 and polymeric actuator 102. The electrolyte also includes a lower electrolyte portion 112L that is in contact with the lower electrode 108. When power supply 101 passes current through electrode set 104, this results in a pH difference between upper electrolyte portion 112U and lower electrolyte portion 112L and more importantly modulates the pH of upper electrolyte portion 112U that is in contact with polymeric actuator 102. In one embodiment of
Polymeric actuator 102 is pH responsive and expands or contracts in response to a pH change in the upper electrolyte portion 112U. There are two types of polymeric actuators 102 that may be used including an “acid-responsive” polymeric actuator and a “base-responsive” polymeric actuator. An “acid responsive” polymeric actuator will expand in response to a decreased pH in upper electrolyte portion 112U surrounding polymeric actuator 102. This can be accomplished by providing a positive bias of electrode 106 relative to electrode 108. Applying the positive bias causes current to flow from electrode 106 to electrode 108 and causes a positive ion concentration in the upper electrolyte portion 112U surrounding actuator 102 to increase. Thus the upper electrolyte portion 112U surrounding actuator 102 becomes acidic (lower pH) and causes actuator 102 to expand. If the bias is reversed the upper electrolyte portion 112U surrounding actuator 102 becomes more basic which causes an opposite effect on actuator 102.
A “base responsive” polymeric actuator 102 also may be used. In that case, applying a negative bias to electrode 106 relative to electrode 108 will cause the pH in the upper electrolyte portion 112U surrounding polymeric actuator to increase which will in turn cause the base responsive polymeric actuator 102 to expand. When polymeric actuator 102 expands, it causes the entire actuator assembly 105 to expand.
An alternative design of an actuator assembly 120 utilizing both acid responsive and base responsive actuators is depicted in
When a positive bias current is applied between top electrode 126 and bottom electrode 128 and pH of the top electrolyte 132 decreases while the pH of the bottom electrolyte 134 increases. The decreased pH (acidity increase) of the top electrolyte 132 causes acid responsive polymeric actuator 122 to expand while the increased pH (more basic) of bottom electrolyte 143 causes base responsive polymeric actuator 124 to expand. Having two layers of actuators may double the total displacement obtainable for the actuator assembly 120. It is anticipated that additional layers of polymeric actuators with alternating layers of acid responsive and base responsive polymeric actuators can be used to further increase the maximum expansion of actuator assembly 120.
An alternative embodiment of an actuator assembly 140 is depicted with respect to
In one embodiment actuator 142 is an acid responsive polymeric actuator and container 144 is a breakable container that contains an acidic solution. Upon breaking open container 144, the acidic solution lowers the pH of electrolyte 146 causing actuator 142 to expand. When actuator 142 expands, it in turn causes housing 148 to expand.
In another embodiment actuator 142 is a basic responsive polymeric actuator and container 144 is a breakable container that contains a basic solution. Upon breaking open container 144, the basic solution raises the pH of electrolyte 146 causing actuator 142 to expand. When actuator 142 expands, it in turn causes housing 248 to expand.
Another actuator 2 of the present invention with various details left out is depicted in plan view with respect to
The actuator 2 is further depicted with respect to
Carrier 2 has a plurality of wells or holes 12 formed therein that define openings 14 along surface 8 of carrier 2. Each of the wells 12 supports one of the discrete polymeric actuators 6. In the illustrated embodiment each discrete polymeric actuator 6 has a volume that is primarily contained within a well 12. A small portion 16 of the volume of each polymeric actuator 6 may extend above the well 12.
Each of the discrete polymeric actuators 6 is formed from a material that is volumetrically responsive to a change in pH within an electrolyte 22 that is in contact with discrete polymeric actuators 6. Stated another way, when the electrolyte 22 changes pH, the volume of each discrete polymeric actuator 6 also changes. To cause this change in pH, actuator 2 includes an apparatus for changing the pH of the electrolyte 22.
In the depicted embodiment, the apparatus for changing the pH includes an electrode set which includes an upper electrode 18, a lower electrode 20, and a porous separator membrane 24 that separates electrode 20 from the electrolyte solution 22 in contact with polymeric actuators 6. Applying a current between upper electrode 18 and lower electrode 20 causes an ionic concentration change in electrolyte 22 which is logarithmically related to the pH of electrolyte 22.
In one embodiment, the discrete polymer actuators 6 are formed from an “acid responsive” polymer that expands in response to a decrease in pH of the surrounding electrolyte 22. By providing a positive bias at electrode 18 relative to electrode 20, the pH in surrounding electrolyte 22 decreases causing discrete polymeric actuators 6 to expand. To improve contact between polymeric actuators 6 and electrolyte solution 22, carrier 22 is formed from a “micro porous polymeric material” such as porous polyethylene.
The polymeric actuators are constrained such that when they expand, they tend to generate a net force and displacement primarily along axis 10C. Because most of the volume of each actuator 6 is contained within a well 12, the net expansion must be in an upward direction within each well 12. Further, the actuators 6 are packed together closely enough to constrain a “mushrooming” effect of the actuators 6 above the surface 8 to further enhance the net upward motion and force generated by actuators 6 during expansion.
The actuator assembly 2 includes a housing 26 that includes an upper portion 26A, lower portion 26B, and a compliant portion 26C. When the actuators 6 push upward they have the effect of expanding housing 26 along the axis 10C in response to the change in pH. In one embodiment actuator electrode 18 is rigid and functions as a rigid platen. Actuators 6 may push against electrode 18 that in turn pushes up against top portion 26A.
Actuator assembly 38 also includes an outer housing 46 upon which is formed a lower electrode 48. A portion 41 of carrier 40 abuts and seals against the housing 46 such that carrier 40 functions as a porous separator to separate lower electrode 48 from electrolyte 45 that surrounds polymeric actuators 44. A positive bias of an electrode 42 with respect to lower electrode 48 will tend to lower the pH within the electrolyte 45 that is adjacent to the lower electrode 48. In the case of acid responsive polymeric actuators 44 the volume of each discrete polymeric actuator 44 will tend to increase with the application of a positive bias to its corresponding or adjacent electrode 42. Except for the formation of electrode 48, the outer housing 46 is similar in construction to housing 26 described with respect to
When a positive bias is applied to upper electrode 76 relative to lower electrode 78 this has the effect of reducing pH in the vicinity of actuators 72 and increasing the pH in the vicinity of actuators 74. Therefore all of the actuators 72 and 74 will expand under this bias wherein electrode 76 has a positive bias with respect to electrode 78. This design has the advantage of increasing maximum displacement of actuator 64 relative to an axis of 80. Actuator assembly 64 includes an outer housing 82 that is similar to the outer housing 26 described with respect to
An exemplary embodiment of a system 202 according to another aspect of the present invention is schematically depicted with respect to
In other preferred embodiments controller 206 may be in communication with remote or wireless devices to allow for remote activation, deactivation and programming changes when needed. This may be done through IR (infrared), WIFI, RF (radio frequency), Magnetic or other types of wireless communication and would also allow for remote monitoring of an environment around system 202, and feedback from sensors monitoring performance and results of the activity of actuator 210.
In a preferred embodiment system 202 also includes a sensor 212 configured to sense characteristics within actuator 210 such as an electrical impedance within actuator 210. In an exemplary embodiment sensor 212 is integrated within power supply 204 and is configured to sense the electrical impedance between two electrodes of electrode set 208. In alternative embodiments sensor 212 may be separate from power supply 204. In additional alternative embodiments sensor 212 may sense parameters such as ion concentration, pH, complex impedance, resistance, resistivity, inductance, capacitance, and/or other measured parameters within actuator 210. Sensor 212 is configured to provide information to controller 206 that is indicative of the measured parameters. Controller 206 is configured to modify a current versus time profile to be applied to electrode set 208 in response to information received from sensor 212.
In a preferred embodiment actuator assembly 210 is configured to expand linearly along an axis A in response to charge that is passed between electrodes 216 and 218 of electrode set 208. Controller 208 receives information from sensor 212 that is indicative of the linear expansion of actuator assembly 210 that includes an impedance measured between electrodes 216 and 218. Controller 208 is configured to modify an amount of charge being passed between electrodes 216 and 218 in order to control the linear expansion of actuator assembly 210 to a predetermined value.
Actuator assembly 210 includes a polymeric actuator 214 and associated electrode set 208 including upper electrode 216 and lower electrode 218. The electrode set 208 and the polymeric actuator 214 are contained within housing 220. Contained within housing 220 is an electrolyte solution 222 that immerses actuator 214 and electrode set 208. Separating upper electrode 216 from lower electrode 218 is a porous separator membrane 226. The electrolyte includes an upper electrolyte portion 222U that is in fluidic and electrical contact with upper electrode 216 and polymeric actuator 214. The electrolyte 222 also includes a lower electrolyte portion 222L that is in fluidic and electrical contact with the lower electrode 218.
When power supply 204 passes current through electrode set 208, this results in an ionic concentration or pH difference between upper electrolyte portion 222U and lower electrolyte portion 222L and more importantly modulates the ionic concentration or pH of upper electrolyte portion 222U that is in contact with polymeric actuator 214. In one embodiment of
Polymeric actuator 214 is pH responsive and will expand or contract in response to a pH change in the upper electrolyte portion 222U. Two types of polymeric actuators 214 that may be used include an “acid-responsive” polymeric actuator and a “base-responsive” polymeric actuator. An “acid-responsive” polymeric actuator will expand in response to a decreased pH in upper electrolyte portion 222U surrounding polymeric actuator 214. This can be accomplished by providing a positive bias of electrode 216 relative to electrode 218. Applying the positive bias causes current to flow from electrode 216 to electrode 218 and causes a positive ion concentration in the upper electrolyte portion 222U surrounding actuator 214 to increase. Thus the upper electrolyte portion 222U surrounding actuator 214 becomes acidic (lower pH) and causes actuator 214 to expand. If the bias is reversed the upper electrolyte portion 222U surrounding actuator 214 becomes more basic which causes an opposite effect on actuator 214.
A “base responsive” polymeric actuator 214 may also be used. In that case, applying a negative bias to electrode 216 relative to electrode 218 will cause the pH in the upper electrolyte portion 222U surrounding polymeric actuator to increase which will in turn cause the base responsive polymeric actuator 214 to expand. When the polymeric actuator 214 expands, it causes the entire actuator assembly 210 to expand.
An exemplary operation of actuator system 202 is depicted in flow chart form with respect to
In step 230, power supply 204 deliveries a first forward bias charge between electrodes 216 and 218 during a first time period. This modifies the pH of the upper electrolyte 222U. Polymeric actuator 214 expands (or contracts) in response to the pH change from a first volume to a second volume. At the end of the first time period, the volume of polymeric actuator 214 is expanding (or contracting) at a first expansion (or contraction) rate. In a preferred embodiment, the power supply 204 adjusts a forward bias charge magnitude in response to information received from sensor 212 in order to achieve a predetermined second volume for polymeric actuator 214.
In step 232, power supply 204 delivers a first negative bias charge between electrodes 216 and 218 during a second time period. This oppositely changes the pH of upper electrolyte portion 222U relative to step 230 and primarily moves the pH toward a relatively neutral state. The polymeric actuator rate of expansion (or contraction) slows in response. In a preferred embodiment power supply 204 adjusts the negative bias charge magnitude in response to information from sensor 212 to reduce the magnitude of the rate of expansion to a magnitude that approaches zero as closely as possible. In one embodiment the rate of expansion is reduced to less than 50% of the first expansion rate. In other embodiments magnitude of the rate of expansion is reduced to less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1% of the first expansion rate. The magnitude of the first negative bias charge is less than the magnitude of the first positive bias charge since the negative bias charge is being used only to stop the volume change of actuator 214, whereas the first positive bias charge is being used to change the volume from a first volume to a predetermined second volume.
In step 234 power supply 204 suspends operation for a third time period during which the volume of actuator assembly 210 does not change significantly. In step 236 power supply 204 delivers a second forward bias charge between electrodes 216 and 218 during a fourth time period. Polymeric actuator expands (or contracts) from a third volume to a fourth volume in response to the delivery of the second forward bias charge. In a preferred embodiment, the third volume is equal to the second volume. Step 236 is similar to step 230 except that in an exemplary embodiment the amount of charge transferred in step 236 may be different than in step 230. This will be discussed in infra.
Step 238 is similar to step 232. During step 238, power supply 238 delivers a second reverse bias charge to electrode set 208 during a fifth time period to slow a magnitude of a rate of expansion (or contraction) of actuator 214. In step 240, operation of power supply power supply 204 is suspended during a sixth time period.
After step 240, the steps of applying forward bias charge (similar to steps 230 and 236) for expansion (or contraction), applying negative bias charge to slow or stop expansion (similar to steps 232 and 238), and suspending operation (similar to 234 and 240) may continue until actuator 214 reaches a maximum (or minimum) volume.
In an exemplary embodiment system 202 is configured to linearly expand actuator assembly 210 along an axis A in approximately equal sized steps. In this exemplary embodiment an apparatus similar to that depicted with respect to
An exemplary graph of current versus time 242 delivered by power supply 204 to electrode set 208 is depicted with respect to
At an initial time 244 actuator 214 has an initial volume V. During a first time period 246 power supply 204 delivers a positive current level 248. This corresponds to step 230 of
During a second time period 250, power supply 204 delivers a negative current level 252. Second time period 250 is of lesser magnitude than first time period 246. Second time period 250 may correspond to step 232 of
During a fourth time period 256 power supply 204 delivers a positive current level 258. Fourth time period 256 may be of longer duration than first time period 246. Fourth time period 256 may correspond to step 236 of
While
Another embodiment of the invention is similar to that depicted in
While polymeric actuator 214 is depicted in
An actuator 262 of the present invention with various details left out is depicted in plan view with respect to
The actuator 262 is further depicted with respect to
Carrier 262 has a plurality of wells or holes 272 formed therein that define openings 274 along surface 268 of carrier 262. Each of the wells 272 supports one of the discrete polymeric actuators 266. In the illustrated embodiment each discrete polymeric actuator 266 has a volume that is primarily contained within a well 272. A small portion 276 of the volume of each polymeric actuator 266 may extend above the well 272.
Each of the discrete polymeric actuators 266 is formed form a material that is volumetrically responsive to a change in pH within an electrolyte 282 that is in contact with discrete polymeric actuators 206. Stated another way, when the electrolyte 282 changes pH, the volume of the each discrete polymeric actuator 266 also changes. To cause this change in pH, actuator 262 includes an electrode set 208 coupled to a power supply 204 (not shown in
The electrode set 208 includes an upper electrode 278 and a lower electrode 280. Actuator assembly 262 also includes a porous separator membrane 224 that separates electrode 280 from the electrolyte solution 282 in contact with polymeric actuators 266. Applying a current between upper electrode 278 and lower electrode 280 causes an ionic concentration change in electrolyte 282 which is logarithmically related to the pH of electrolyte 282.
In one embodiment, the discrete polymer actuators 266 are formed from an “acid responsive” polymer that expands in response to a decrease in pH of the surrounding electrolyte 282. By providing a positive bias at electrode 278 relative to electrode 280, the pH in surrounding electrolyte 282 decreases causing discrete polymeric actuators 266 to expand. To improve contact between polymeric actuators 266 and electrolyte solution 282, carrier 282 is formed from a “micro porous polymeric material” such as porous polyethylene.
The polymeric actuators are constrained such that when they expand, they tend to generate a net force and displacement primarily along axis 270C. Because most of the volume of each actuator 266 is contained within a well 272, the net expansion must be in an upward direction within each well 272. Further, the actuators 266 are packed together closely enough to constrain a “mushrooming” effect of the actuators 266 above the surface 268 to further enhance the net upward motion and force generated by actuators 266 during expansion.
The actuator assembly 262 includes a housing 286 that includes an upper portion 286A, lower portion 286B, and a compliant portion 286C. When the actuators 266 push upward they have the effect of expanding housing 286 along the axis 270C in response to the change in pH. In one embodiment actuator electrode 278 is rigid and functions as a rigid platen. Actuators 266 may push against electrode 278 that in turn pushes up against top portion 286A.
Other preferred embodiments may include multiple actuators 210 attached to a single controller 206 and power supply 204 with the electrodes 208 entering and exiting the exterior to continue on from first actuator package to the next actuator package to enable stacking or linear lines of actuators all in electrical connection.
During the steps 292-298, power supply 204 is transferring charge between electrodes 216 and 218 under control of controller 206. Therefore controller 206 is executing the steps 292-298 utilizing power supply 204.
The pH of electrolyte 222U is modulated when current is passed between electrodes 216 and 218. For the purposes of
Sensor 212 monitors the state of actuator assembly 210. Sensor 212 provides information to controller 206 that is indicative of an expansive state of polymeric actuator 214 and actuator assembly 210. Controller 206 is configured to modify operation in response to the information in order to control the expansion of actuator 210 to within a predetermined range.
The step 290, power supply 204 transfers a first forward bias charge Q1 between electrodes 216 and 218 during a time T1 and at an average rate I1. In response to the transfer of charge Q1, actuator 210 expands from a first volume to a second volume at a rapid rate due to a relatively high current level I1. During this expansion, a medication pump utilizing actuator system 202 may deliver a medication bolus roughly during time T1.
According to optional step 292, power supply 104 transfers a reverse bias charge during a time T2. During time T2, the rate of expansion is either reduced to a lower rate or is substantially halted.
According to step 294, power supply 204 transfers a second forward bias charge Q3 over a time T3 and at a current level I3. Current level I3 is lower than current level I1. Current level I3 may be less than 50% than current level I1. Time T3 is considerably longer than time T1. Time T3 may be more than ten times as long as time T1. In the case of a portable IV pump, the pump would be delivering a basal rate during time T3.
In step 296, steps of 290-294 are repeated (possibly including optional step 292) in which the parameters used may change. For example charge Q1 (the forward bias charge) may be increased in order to get the same size of bolus in the case of a portable IV pump. Step 298 is again a repeat of steps 290-294 in which parameters may change. Steps 298 can then be repeated again and again. In the embodiment in which system 202 is a portable IV pump this may continue until the pump has discharged all available fluid. Alternatively the actuator 214 may be returned to an initial state and then the method of
Another aspect of the present invention is described below, with reference to
Critical high potency medications such as Schedule II pain therapeutics are often administered to patients at healthcare facilities. Schedule II pain medications are particularly important for patients having undergone surgeries or having conditions involving acute pain. In such a situation a doctor writes an order or prescription for treatment of the patient. The order is filled or verified by the facility pharmacy and may need to be renewed, e.g., every 48 to 96 hours. The order can then be dispensed by an automated cabinet system to a caregiver (e.g., a nurse) as required by the patient. The process flow for receiving and administering pain therapies according to a current process is depicted in
The situation according to
The caregiver must perform the steps according to steps 304-308 with a second caregiver as witness in order to assure proper handling and documentation for a Schedule II pain therapy medication. This is partly because such medications have been subject to substance abuse and theft.
In step 306, a glass cylinder of the medication is removed from the dispenser system. In the event that the full cylinder is not required in step 308, the caregiver loads a syringe and discards extra medication while the second caregiver observes and documents wastage medication. At this stage a computation of the correct dosage must often be calculated by the caregiver according to the concentration of the medication. Given the urgency of the situation and other distractions, errors can easily be made at this step that may result in a hazard to the patient and/or an insufficient dosage to eliminate the pain.
After the syringe is loaded the caregiver injects the medication into the patient at a step 310 and documents the dose given along with the pain score computation at a step 312. Disadvantages of this methodology include delays in administering the medication, potential errors, and issues with narcotic diversion. Additionally manual and time consuming patient-specific record keeping has to be completed and entered into the healthcare facility's information system on an ongoing basis further consuming the caregivers time.
Insufficient or delayed pain therapy may impair a patient's ability to heal and leave the healthcare facility. What is needed is a new process that addresses these issues while simplifying the process of administering the medication.
A process flow and device of the present invention is depicted in
At the healthcare facility 322 a doctor 324 may place an order for device 316. The pharmacy then makes the device available to a caregiver 326 via an automated dispensing system 328. The caregiver can then administer medication from device 316 to patient 330.
Device 316 is small and configured to be mounted to the body of patient 330. Device 316 includes therapeutic liquid 332 configured for delivery to patient 330. Device 316 includes a pump or actuator 334 under control of electronics 336 that controllably displaces the liquid 332 to the patient's body. The electronics 336 include programming instructions and parameters that govern the proper displacement of the liquid 332 to the patient 330.
The electronics 336 are configured to receive data or code inputs at different times during the process flow depicted in
The electronics 336 are described in greater detail in block diagram form in
Programming interface 348 is configured to receive inputs at factory 314 and filling facility 318. Programming interface 348 may include a wireless portion for receiving wireless inputs and/or a data connector. In one embodiment programming interface 348 is configured to receive portions or all of an operating system during the manufacture of device 316. Programming interface 348 is configured to receive parameters governing the operation of device 316 while device 336 is in filling and programming facility 318.
User interface 350 may include various features such as a display, buttons, LED indicator lights, audio indicators, as well as a wireless interface by which a caregiver can remotely make inputs. User interface 350 is configured to be utilized by caregiver 326. User interface 350 is generally not configured to alter the parameters received through programming interface 348 but generally only allows operation of device 316 within bounds provided by the parameters.
In an exemplary embodiment, electronics 336 include an energy monitor 354 that is configured to monitor current delivered by actuator driver 346 to actuator 334. In this embodiment actuator 334 includes a polymeric actuator that is configured to change volume and displace fluid from a liquid container or bag 332 in response to an amount of charge received from actuator driver 346. Information from energy monitor 354 is fed back to controller 344 to assure that a specified amount of charge is passed from actuator driver 346 to actuator 334. Other embodiments of device 316 can also be contemplated for moving fluid such as a pump that may require other forms of energy monitors.
Sensor 352 may be a pressure sensor configured to sense a pressure exerted on the therapeutic liquid by actuator 334. The sensed pressure may be used to control operation of actuator driver 346. The sensor can also be utilized as a secondary feedback path to provide redundant monitoring of the actuator for safety purposes. Other types of sensors 352 are contemplated to be used in device 316 such as displacement sensors, capacitive sensing, inductive sensing, to name a few.
Device 316 also includes a self contained power source or battery 356 that provides power to a voltage regulator 358. Voltage regulator 358 provides appropriate logic voltages to electronics 336.
Device 316 is depicted in simplified schematic form in
Device 316 includes a user interface 350 that may include any or all of keys 364, display 366, and an LED indicator 368. The user interface 350 may also include an external wireless device (not shown) that is configured to communicate with controller 336 using a wireless link such as RFID, IR, Bluetooth or other forms of wireless communication. The user interface may provide status and historical therapeutic and event information to the operator via wired or wireless methods.
Device 316 may also include a security measure or device configured to limit access to use of device 316. Various security measures may include physical keys or user interfaces requiring the caregiver 326 to enter a code to unlock or enable the device 316.
An example of a security measure includes a removable label 369 having a code that is utilized to unlock device 316 once the label is removed. This code may be entered by the pharmacist or caregiver for the purpose of activating device 316 and enabling medication to be administered by device 316. The label may be kept in a secured location such as upon a patient chart. Other examples of security measures include wireless devices that interface with device 316 and utilize a security code mechanism, proximity sensing mechanism or combination thereof.
A method of providing device 316 to healthcare facility 322 caregivers is described with respect to
According to 372, a medication type and concentration is selected based on a particular class of patient conditions from among a plurality of different classes of patient conditions. Based upon the particular class, device 316 is filled with the medication type and concentration in step 374. In step 376, parameters are stored on controller 344 that are specific to the (1) class of patient conditions, (2) the type of medication, and (3) the concentration of the medication. The parameters govern the operation of the device 316 according to safety and efficacy requirements of the particular type and concentration of the medication. Some examples of these parameters follow:
Bolus Dosage Selection: A selection or range of possible bolus dosages are provided consistent with the class of patient conditions, the medication type, and concentration. In one exemplary embodiment there is no limits on the dosages but there are “soft guardrails” wherein the device 316 is configured to issue warnings when a bolus dosage or sequence of dosages have values that are outside of a recommended range. The warning may be a visual and/or audible warning issued from user interface 350. The warning may include warning information that is transmitted wirelessly to another device such as a cellular phone or network, a computer network, a PDA, or any other device that can provide a warning to a caregiver.
Maximum Dosage Over Specified Time Periods: For example, there may be an upper limit on the total dosage that should be administered over 24 hours. In one embodiment the device 316 may be configured to issue a warning to the caregiver if the dosage over a specified time period is above a threshold.
Minimum Dosage Since the patient is of a certain patient class there may be a lower limit dosage below which is insufficient to reduce patient suffering and/or facilitate recovery. If a caregiver operates the device below the minimum, then a warning may be generated.
In one embodiment of the invention, step 374 is performed before step 372. In another embodiment, step 374 is performed after step 376. In yet another embodiment steps 374 and 376 are performed concurrently.
Once the device 316 has been filled and programmed according to steps 374 and 376, the device is placed in inventory of healthcare facility 322 in a step 378. According to steps 374 and 376, device 316 has been filled and programmed for a specific class of patient conditions. The parameters that are inputted according to step 376 cannot be overridden by a caregiver and are preferably stored in a write once or write protected memory in controller 336 to prevent any change to them.
A method of use of device 316 is depicted according to
According to step 380, the doctor 324 produces a prescription for the pain medication which is transferred to pharmacy 320. A pharmacist reviews the prescription, selects device 316, and verifies the order according to step 382. The pharmacist will select a device 316 having that is pre-configured with parameters, medication type, and concentration that are consistent with the prescription.
Once the pharmacist has verified the proper device according to the order, the pharmacist activates the device 316 according to step 384. According to step 386 the pharmacist then utilizes an automated dispensing system to transfer the device to caregiver 326. The caregiver 326 then places upon the patient and couples the device via an administration route (conduit and coupling means) 362 to the patient 330 according to step 388. In an exemplary embodiment, administration route is subcutaneous. In step 390, the caregiver 326 enters a code into device 316 that unlocks the device and enables administration of medication to patient 330. In step 392 the caregiver manipulates the user interface 350 to administer the medication to patient 330.
The method of this invention has substantial benefits over the current methods of administration using syringes. This is illustrated by comparing
At this point several examples of pre-configured devices 316 will be disclosed. Each of these devices are initially the same design produced in factory 314 but become configured for a particular class of patients within filling within facility 318.
According to this example of step 374 of
According to this example of step 374 the device 316 is filled with hydromorphone having a 10 mg/ml concentration. In step 376 the device receives bolus dose parameters enabling the caregiver to provide doses of 0.2 mg (0.02 ml), 0.25 mg (0.025 ml), 0.5 mg (0.05 ml), 1 mg (0.1 ml), and 2 mg (0.02 ml).
According to this example of step 374 the device 316 is filled with fentanyl having a concentration of 0.05 ml/mg. The device receives bolus dose parameters to enable the caregiver to inject boluses of 0.015 mg (0.3 ml), 0.025 mg (0.05 ml), 0.05 mg (0.1 ml), 0.075 mg (0.15 ml), and 0.1 mg (0.2 ml).
The present invention has been described as delivering Schedule II controlled substances for pain relief. However the present invention may deliver other fluids such as pharmaceutical drugs, other controlled substances, vitamins, hormones, hydration liquids, biologics, liquids with site specific identification or therapy molecular tags, insulin, immune system therapeutics such as Enbrel & Humira, and gene therapeutics. In addition other non-opioid medications may be used to supplement analgesia, including non-steroidal anti-inflammatory medications and low-dose anti-depressants.
Referring now to
Area actuator assembly 508 is responsive to electrical signals received from control electronics 510. Area actuator assembly 508 is configured to expand and press upon collapsible reservoir 506 in response to charge or current received from electronics 510. Area actuator 510 will be described in more detail with respect to
When area actuator assembly 508 expands and compresses collapsible reservoir 506, fluid within collapsible reservoir 506 is displaced under pressure from reservoir 506, through conduit 512, and to patient 514. In a preferred embodiment a subcutaneous fluid interface exists between conduit 512 and patient 514.
Disposed upon outer housing 504 is a user interface 516. User interface 516 may includes any or all of input keys or buttons 518, display 520, and LED indicator lights 522. User interface 516 may also include a wireless device (not shown) utilized to control medication delivery device 502, and facilitate access to electronic medical records stored in the device memory. The user interface is also configured to facilitate secure access to the device when necessary.
Inner contents of actuator assembly 508 include a responsive material 526 disposed between electrodes 528 including upper electrode 528U and lower electrode 528L. A porous separator membrane 530 separates upper electrode 528U from sealed region 525. Also within sealed housing 524 is an electrolyte solution 532 including an upper electrolyte solution 532U that is between separator membrane 530 and upper electrode 528U and a lower electrolyte solution 532L that is between membrane 530 and housing 524.
In a preferred embodiment responsive material 526 is polymeric actuator 526 that is responsive to pH changes within lower electrolyte solution 532L. Electronics 510 are configured to pass charge between electrodes 528 and, in doing so, modulate the pH within the lower electrolyte 532L by changing the charge distribution within housing 524. There are two types of polymeric actuators 526 that may be used within actuator assembly 508 including an “acid-responsive” polymeric actuator and a “base-responsive” polymeric actuator. An “acid-responsive” polymeric actuator will expand in response to a decreased pH in electrolyte 532L surrounding polymeric actuator 526. This can be accomplished by providing a positive bias of electrode 528U relative to electrode 528L. Applying the positive bias causes current to flow from electrode 528U to electrode 528L and causes a positive ion concentration in the electrolyte 532L surrounding actuator 526 to increase. Thus the electrolyte 532L surrounding actuator 526 becomes acidic (lower pH) and causes actuator 526 to expand. (If the bias is reversed the electrolyte 532L surrounding actuator 526 becomes more basic which causes an opposite effect on actuator 526.)
A “base responsive” polymeric actuator may also be used. In that case, applying a negative bias to electrode 528L relative to electrode 528U will cause the pH in the electrolyte 532L surrounding polymeric actuator to increase which will in turn cause the base responsive polymeric actuator 526 to expand. When polymeric actuator 526 expands, it causes the entire actuator assembly 508 to expand.
Other designs of actuator assemblies 508 can be envisioned using multiple polymeric actuators 526 and more than two electrodes 528. These alternative designs may be of various geometric shapes and sizes and be substituted into the medication delivery device of the present invention without departing from the broad scope of the invention.
A resulting medication delivery device 502 is in top plan view in
Pockets 534 and 536 are better illustrated in
Device 502 may also include a fluid fill port 513 for filling reservoir 506 with fluid. Alternatively reservoir 506 may be filled via fluid conduit 512. In a preferred embodiment, fluid fill port 513 or fluid conduit 512 are configured to enable reservoir 506 to be filled in a facility that is separate from the factory within which device 502 is manufactured.
In the embodiments depicted in
In both illustrated embodiments, upper electrode 528U is adjacent to upper support 542. Lower electrode/piston plate 528L or piston plate 546 is adjacent to collapsible reservoir 506. Collapsible reservoir 506 is adjacent to lower support 544.
The reservoir/actuator pocket 534 is approximately square looking upon the lateral axes X and Y. This maximizes volumetric efficiency of the reservoir actuator pocket 534 in terms of volume of fluid delivered relative to size of device 502. Leading to the patient is a conduit 512 that, in an exemplary embodiment, exits pocket 543 on a side that opposes the electronics 510 relative to axis X. In addition, the electrical lead through 540 is on an opposing side of actuator pocket 534 relative to conduit 512 and relative to axis X.
Other embodiments can be envisioned with other arrangements and configurations of fluid bags and actuators. The scope of the present invention is not intended to be limited except as recited in the claims.
This application claims priority from U.S. Provisional Application Ser. Nos. 61/241,375, 61/244,884, 61/267,334 and 61/295,247, filed respectively on Sep. 10, 2009, Sep. 23, 2009, Dec. 7, 2009 and Jan. 15, 2010, the contents of which are incorporated herein in their entireties.
This invention in part was made with U.S. government support under (IIP 0848528) awarded by the National Science Foundation. The U.S. Government may have certain rights in the invention.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US2010/048489 | 9/10/2010 | WO | 00 | 3/12/2012 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2011/032011 | 3/17/2011 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3922328 | Johnson | Nov 1975 | A |
| 4034380 | Isayama | Jul 1977 | A |
| 4111202 | Theeuwes | Sep 1978 | A |
| 4190411 | Fujimoto | Feb 1980 | A |
| 4203440 | Theeuwes | May 1980 | A |
| 4299220 | Dorman | Nov 1981 | A |
| 4327725 | Cortese et al. | May 1982 | A |
| 4395719 | Majewski et al. | Jul 1983 | A |
| 4423166 | Moriarty et al. | Dec 1983 | A |
| 4432699 | Beckman et al. | Feb 1984 | A |
| 4449893 | Beckman | May 1984 | A |
| 4449983 | Cortese et al. | May 1984 | A |
| 4507363 | Chow et al. | Mar 1985 | A |
| 4538607 | Saul | Sep 1985 | A |
| 4551139 | Plaas et al. | Nov 1985 | A |
| 4559038 | Berg et al. | Dec 1985 | A |
| 4595583 | Eckenhoff et al. | Jun 1986 | A |
| 4624847 | Ayer et al. | Nov 1986 | A |
| 4624848 | Lee | Nov 1986 | A |
| 4650469 | Berg et al. | Mar 1987 | A |
| 4655767 | Woodward et al. | Apr 1987 | A |
| 4663149 | Eckenhoff et al. | May 1987 | A |
| 4675174 | Eckenhoff | Jun 1987 | A |
| 4723958 | Pope et al. | Feb 1988 | A |
| 4772474 | Eckenhoff et al. | Sep 1988 | A |
| 4781714 | Eckenhoff et al. | Nov 1988 | A |
| 4808084 | Tsubouchi et al. | Feb 1989 | A |
| 4810535 | McCollum et al. | Mar 1989 | A |
| 4842493 | Nilsson | Jun 1989 | A |
| 4863456 | Stephens et al. | Sep 1989 | A |
| 4948592 | Ayer et al. | Aug 1990 | A |
| 4963141 | Eckenhoff | Oct 1990 | A |
| 5000957 | Eckenhoff et al. | Mar 1991 | A |
| 5034229 | Magruder et al. | Jul 1991 | A |
| 5037420 | Magruder et al. | Aug 1991 | A |
| 5059423 | Magruder et al. | Oct 1991 | A |
| 5061242 | Sampson | Oct 1991 | A |
| 5070560 | Wilkinson | Dec 1991 | A |
| 5100933 | Tanaka et al. | Mar 1992 | A |
| 5105983 | Sancoff | Apr 1992 | A |
| 5110596 | Magruder et al. | May 1992 | A |
| 3029743 | Johns | Mar 1993 | A |
| 5192197 | Culp | Mar 1993 | A |
| 5192298 | Culp | Mar 1993 | A |
| 5232702 | Pfister et al. | Aug 1993 | A |
| 5246705 | Venkatraman et al. | Sep 1993 | A |
| 5279544 | Gross et al. | Jan 1994 | A |
| 5279565 | Klein et al. | Jan 1994 | A |
| 5284133 | Burns et al. | Feb 1994 | A |
| 5300299 | Sweet et al. | Apr 1994 | A |
| 5304121 | Sahatjian | Apr 1994 | A |
| 5327041 | Culp | Jul 1994 | A |
| 5328696 | Noel | Jul 1994 | A |
| 5336057 | Fukuda et al. | Aug 1994 | A |
| 5348746 | Dong et al. | Sep 1994 | A |
| 5354264 | Bae et al. | Oct 1994 | A |
| 5376378 | Li et al. | Dec 1994 | A |
| 5380760 | Wendel et al. | Jan 1995 | A |
| 5412821 | Wilkinson | May 1995 | A |
| 5429585 | Liang | Jul 1995 | A |
| 5431921 | Thombre | Jul 1995 | A |
| 5474783 | Miranda et al. | Dec 1995 | A |
| 5498255 | Wong | Mar 1996 | A |
| 5546932 | Galli | Aug 1996 | A |
| 5573668 | Grosh et al. | Nov 1996 | A |
| 5587237 | Korpman et al. | Dec 1996 | A |
| RE35474 | Woodard et al. | Mar 1997 | E |
| 5618899 | Appelt et al. | Apr 1997 | A |
| 5622482 | Lee | Apr 1997 | A |
| 5630709 | Bar-Cohen | May 1997 | A |
| 5633009 | Kenealy et al. | May 1997 | A |
| 5645855 | Lorenz | Jul 1997 | A |
| 5656286 | Miranda et al. | Aug 1997 | A |
| 5674192 | Sahatjian et al. | Oct 1997 | A |
| 5687748 | Conrad et al. | Nov 1997 | A |
| 5692256 | Kramer et al. | Dec 1997 | A |
| 5714160 | Magruder et al. | Feb 1998 | A |
| 5718700 | Edgren et al. | Feb 1998 | A |
| 5779668 | Grabenkort | Jul 1998 | A |
| 5798600 | Sager et al. | Aug 1998 | A |
| 5810001 | Genga et al. | Sep 1998 | A |
| 5823178 | Lloyd et al. | Oct 1998 | A |
| 5891463 | Bello et al. | Apr 1999 | A |
| 5916968 | Hariharan et al. | Jun 1999 | A |
| 5939477 | Pretzer et al. | Aug 1999 | A |
| 5951999 | Therriault et al. | Sep 1999 | A |
| 5954706 | Sahatjian | Sep 1999 | A |
| 5961298 | Bar-Cohen | Oct 1999 | A |
| 5979892 | Smith | Nov 1999 | A |
| 5997501 | Gross et al. | Dec 1999 | A |
| 6004115 | Da Costa | Dec 1999 | A |
| 6010485 | Buch-Rasmussen et al. | Jan 2000 | A |
| 6024976 | Miranda et al. | Feb 2000 | A |
| 6066325 | Wallace et al. | May 2000 | A |
| RE36754 | Noel | Jun 2000 | E |
| 6074178 | Bishop et al. | Jun 2000 | A |
| 6074179 | Jokela | Jun 2000 | A |
| 6106245 | Cabuz | Aug 2000 | A |
| 6109852 | Shahinpoor et al. | Aug 2000 | A |
| 6143138 | Becker | Nov 2000 | A |
| 6152898 | Olsen | Nov 2000 | A |
| 6157113 | Hunter et al. | Dec 2000 | A |
| 6165155 | Jacobsen et al. | Dec 2000 | A |
| 6174546 | Therriault et al. | Jan 2001 | B1 |
| 6180133 | Quan et al. | Jan 2001 | B1 |
| 6183434 | Eppstein | Feb 2001 | B1 |
| 6184608 | Cabuz | Feb 2001 | B1 |
| 6193996 | Effing et al. | Feb 2001 | B1 |
| 6206850 | O'Neil | Mar 2001 | B1 |
| 6210712 | Edgren et al. | Apr 2001 | B1 |
| 6213739 | Phallen et al. | Apr 2001 | B1 |
| 6221383 | Miranda et al. | Apr 2001 | B1 |
| 6223369 | Maier et al. | May 2001 | B1 |
| 6249076 | Madden et al. | Jun 2001 | B1 |
| 6277401 | Bello et al. | Aug 2001 | B1 |
| 6312715 | Cantor et al. | Nov 2001 | B1 |
| 6316022 | Mantelle et al. | Nov 2001 | B1 |
| 6319245 | Berrigan | Nov 2001 | B1 |
| 6336907 | Dono et al. | Jan 2002 | B1 |
| 6337086 | Kanios et al. | Jan 2002 | B1 |
| 6352715 | Hwang et al. | Mar 2002 | B1 |
| 6365178 | Venkateshwaran et al. | Apr 2002 | B1 |
| 6365185 | Ritschel et al. | Apr 2002 | B1 |
| 6368318 | Visuri et al. | Apr 2002 | B1 |
| 6378292 | Youngner | Apr 2002 | B1 |
| 6387077 | Klibanov et al. | May 2002 | B1 |
| 6392777 | Elliott et al. | May 2002 | B1 |
| 6409716 | Sahatjian et al. | Jun 2002 | B1 |
| 6450773 | Upton | Sep 2002 | B1 |
| 6461644 | Jackson et al. | Oct 2002 | B1 |
| 6464476 | Ross et al. | Oct 2002 | B2 |
| 6471686 | Berrigan | Oct 2002 | B1 |
| 6475639 | Shahinpoor et al. | Nov 2002 | B2 |
| 6490483 | Wallis | Dec 2002 | B2 |
| 6531152 | Lerner et al. | Mar 2003 | B1 |
| 6537194 | Winkler | Mar 2003 | B1 |
| 6578245 | Chatterjee et al. | Jun 2003 | B1 |
| 6632522 | Hyde et al. | Oct 2003 | B1 |
| 6664718 | Pelrine et al. | Dec 2003 | B2 |
| 6682318 | Takeuchi | Jan 2004 | B2 |
| 6682500 | Soltanpour et al. | Jan 2004 | B2 |
| 6685442 | Chinn et al. | Feb 2004 | B2 |
| 6726678 | Nelson | Apr 2004 | B1 |
| 6766817 | Da Silva | Jul 2004 | B2 |
| 6791003 | Choi et al. | Sep 2004 | B1 |
| 6796970 | Klitmose et al. | Sep 2004 | B1 |
| 6809462 | Pelrine et al. | Oct 2004 | B2 |
| 6864295 | Mitarai | Mar 2005 | B2 |
| 6869275 | Dante et al. | Mar 2005 | B2 |
| 6876135 | Pelrine et al. | Apr 2005 | B2 |
| 6902704 | Wilson | Jun 2005 | B2 |
| 6940211 | Pelrine et al. | Sep 2005 | B2 |
| 6948636 | Fischer et al. | Sep 2005 | B1 |
| 6949079 | Westberg et al. | Sep 2005 | B1 |
| 6955923 | Hartting | Oct 2005 | B2 |
| 6960864 | Urano et al. | Nov 2005 | B2 |
| 7285255 | Kadlec et al. | Oct 2007 | B2 |
| 7411792 | Richards et al. | Aug 2008 | B2 |
| 7453187 | Richards et al. | Nov 2008 | B2 |
| 7544260 | Banister et al. | Jun 2009 | B2 |
| 7553903 | Riegel et al. | Jun 2009 | B2 |
| 7700129 | Ito et al. | Apr 2010 | B2 |
| 7820427 | Unger et al. | Oct 2010 | B2 |
| 8190270 | Wingeier et al. | May 2012 | B2 |
| 20010053383 | Miranda et al. | Dec 2001 | A1 |
| 20020004064 | Quan et al. | Jan 2002 | A1 |
| 20020007014 | Hyde et al. | Jan 2002 | A1 |
| 20020010412 | Eppstein | Jan 2002 | A1 |
| 20020015733 | Flashner-Barak et al. | Feb 2002 | A1 |
| 20020043895 | Richards et al. | Apr 2002 | A1 |
| 20020106402 | Hartwig | Aug 2002 | A1 |
| 20020115740 | Beuhler et al. | Aug 2002 | A1 |
| 20020128572 | Chang | Sep 2002 | A1 |
| 20020128618 | Frenz et al. | Sep 2002 | A1 |
| 20020147208 | Fleshner-Barak et al. | Oct 2002 | A1 |
| 20020156463 | Berrigan | Oct 2002 | A1 |
| 20020173745 | Santini et al. | Nov 2002 | A1 |
| 20020183738 | Chee et al. | Dec 2002 | A1 |
| 20020193754 | Cho | Dec 2002 | A1 |
| 20030014036 | Varner et al. | Jan 2003 | A1 |
| 20030051292 | Ferrand et al. | Mar 2003 | A1 |
| 20030054025 | Cantor et al. | Mar 2003 | A1 |
| 20030065303 | Wellman et al. | Apr 2003 | A1 |
| 20030069359 | Torii et al. | Apr 2003 | A1 |
| 20030072792 | Flanigan et al. | Apr 2003 | A1 |
| 20030108590 | Peery et al. | Jun 2003 | A1 |
| 20030124189 | Zentner et al. | Jul 2003 | A1 |
| 20030135158 | Gonnelli | Jul 2003 | A1 |
| 20030139495 | Zentner et al. | Jul 2003 | A1 |
| 20030143257 | Fleshner-Barak et al. | Jul 2003 | A1 |
| 20030152616 | Hartwig | Aug 2003 | A1 |
| 20030153900 | Aceti et al. | Aug 2003 | A1 |
| 20030156953 | Chinn et al. | Aug 2003 | A1 |
| 20030163099 | Wermeling et al. | Aug 2003 | A1 |
| 20030216683 | Shekalim | Nov 2003 | A1 |
| 20030232198 | Lamberti et al. | Dec 2003 | A1 |
| 20040030262 | Fisher et al. | Feb 2004 | A1 |
| 20040068224 | Couvillon et al. | Apr 2004 | A1 |
| 20040092865 | Flaherty et al. | May 2004 | A1 |
| 20040102762 | Gilbert | May 2004 | A1 |
| 20040106893 | Hunter | Jun 2004 | A1 |
| 20040106894 | Hunter | Jun 2004 | A1 |
| 20040112442 | Maerkl et al. | Jun 2004 | A1 |
| 20040133159 | Haider et al. | Jul 2004 | A1 |
| 20040138603 | Cleary et al. | Jul 2004 | A1 |
| 20040142023 | Hartwig | Jul 2004 | A1 |
| 20040149288 | Koch | Aug 2004 | A1 |
| 20040176502 | Raymond et al. | Sep 2004 | A1 |
| 20040176748 | Abramson et al. | Sep 2004 | A1 |
| 20040186419 | Cho | Sep 2004 | A1 |
| 20040202708 | Roehrig et al. | Oct 2004 | A1 |
| 20040204677 | Wellman et al. | Oct 2004 | A1 |
| 20040219194 | Finckh et al. | Nov 2004 | A1 |
| 20040220548 | Heruth et al. | Nov 2004 | A1 |
| 20040234401 | Banister | Nov 2004 | A1 |
| 20040242709 | Oguro et al. | Dec 2004 | A1 |
| 20040265545 | McKean et al. | Dec 2004 | A1 |
| 20050033230 | Alchas et al. | Feb 2005 | A1 |
| 20050043657 | Couvillon | Feb 2005 | A1 |
| 20050058695 | Anigbogu et al. | Mar 2005 | A1 |
| 20050137577 | Heruth et al. | Jun 2005 | A1 |
| 20050137578 | Heruth et al. | Jun 2005 | A1 |
| 20050137579 | Heruth et al. | Jun 2005 | A1 |
| 20050261631 | Clarke et al. | Nov 2005 | A1 |
| 20050273081 | Olsen | Dec 2005 | A1 |
| 20050273082 | Olsen | Dec 2005 | A1 |
| 20050287214 | Ayer et al. | Dec 2005 | A1 |
| 20060021614 | Wermeling et al. | Feb 2006 | A1 |
| 20060076540 | Zama et al. | Apr 2006 | A1 |
| 20060078603 | Nguyen | Apr 2006 | A1 |
| 20060078604 | Kanios et al. | Apr 2006 | A1 |
| 20060084942 | Kim et al. | Apr 2006 | A1 |
| 20060089619 | Ginggen | Apr 2006 | A1 |
| 20060094985 | Aceti et al. | May 2006 | A1 |
| 20060094989 | Scott et al. | May 2006 | A1 |
| 20060110596 | Palasz et al. | May 2006 | A1 |
| 20060135911 | Mittur | Jun 2006 | A1 |
| 20060142875 | Keyes et al. | Jun 2006 | A1 |
| 20060183216 | Handique et al. | Aug 2006 | A1 |
| 20060188558 | Jackson et al. | Aug 2006 | A1 |
| 20060200083 | Freyman et al. | Sep 2006 | A1 |
| 20060204532 | John | Sep 2006 | A1 |
| 20060213674 | Dierker, Jr. et al. | Sep 2006 | A1 |
| 20060276744 | Falk | Dec 2006 | A1 |
| 20070021697 | Ginther et al. | Jan 2007 | A1 |
| 20070031495 | Eppstein et al. | Feb 2007 | A1 |
| 20070052139 | Gilbert | Mar 2007 | A1 |
| 20070078376 | Smith | Apr 2007 | A1 |
| 20070082038 | Gale et al. | Apr 2007 | A1 |
| 20070088267 | Shekalim | Apr 2007 | A1 |
| 20070092570 | Missel et al. | Apr 2007 | A1 |
| 20070098771 | Audett et al. | May 2007 | A1 |
| 20070098772 | Westcott et al. | May 2007 | A1 |
| 20070100355 | Bonde et al. | May 2007 | A1 |
| 20070104771 | Audett et al. | May 2007 | A1 |
| 20070134310 | Nedberge et al. | Jun 2007 | A1 |
| 20070148218 | Gordon | Jun 2007 | A1 |
| 20070190150 | Ito et al. | Aug 2007 | A1 |
| 20070224253 | Franklin | Sep 2007 | A1 |
| 20070260201 | Prausnitz et al. | Nov 2007 | A1 |
| 20070269522 | Wold | Nov 2007 | A1 |
| 20070293826 | Wall et al. | Dec 2007 | A1 |
| 20080009800 | Nickel | Jan 2008 | A1 |
| 20080015494 | Santini, Jr. et al. | Jan 2008 | A1 |
| 20080033228 | Rastegar et al. | Feb 2008 | A1 |
| 20080039791 | Abboud et al. | Feb 2008 | A1 |
| 20080058706 | Zhang et al. | Mar 2008 | A1 |
| 20080063698 | Hartwig | Mar 2008 | A1 |
| 20080091139 | Srinivasan et al. | Apr 2008 | A1 |
| 20080110463 | Hajgato et al. | May 2008 | A1 |
| 20080125744 | Treacy | May 2008 | A1 |
| 20080152592 | Rebec | Jun 2008 | A1 |
| 20080167641 | Hansen et al. | Jul 2008 | A1 |
| 20080183144 | Trautman et al. | Jul 2008 | A1 |
| 20080195018 | Larson et al. | Aug 2008 | A1 |
| 20080208107 | McRae et al. | Aug 2008 | A1 |
| 20080214987 | Xu | Sep 2008 | A1 |
| 20080221552 | Leonard | Sep 2008 | A1 |
| 20080234656 | Pettis et al. | Sep 2008 | A1 |
| 20080312610 | Binks et al. | Dec 2008 | A1 |
| 20080317615 | Banister | Dec 2008 | A1 |
| 20090007904 | Schuster et al. | Jan 2009 | A1 |
| 20090020521 | Blaszczykiewicz et al. | Jan 2009 | A1 |
| 20090026069 | Liao et al. | Jan 2009 | A1 |
| 20090041833 | Bettinger et al. | Feb 2009 | A1 |
| 20090042970 | Herschkowitz et al. | Feb 2009 | A1 |
| 20090048555 | Stryker et al. | Feb 2009 | A1 |
| 20090060986 | Yum et al. | Mar 2009 | A1 |
| 20090085444 | Alvarez Icaza Rivera et al. | Apr 2009 | A1 |
| 20090099545 | Nilsson et al. | Apr 2009 | A1 |
| 20090118662 | Schnall | May 2009 | A1 |
| 20090221971 | Mejlhede et al. | Sep 2009 | A1 |
| 20090227988 | Wood, Jr. et al. | Sep 2009 | A1 |
| 20090232685 | Kamitani et al. | Sep 2009 | A1 |
| 20090317442 | Banister et al. | Dec 2009 | A1 |
| 20100004638 | Gibson | Jan 2010 | A1 |
| 20100074953 | Chaouk et al. | Mar 2010 | A1 |
| 20110172645 | Moga et al. | Jul 2011 | A1 |
| Number | Date | Country |
|---|---|---|
| 2 477 181 | Apr 2004 | CA |
| 1080829 | Mar 2002 | CN |
| 1934776 | Mar 2007 | CN |
| 199 12 606 | Dec 2000 | DE |
| 0 723 982 | Jul 1996 | EP |
| 0 736 556 | Sep 1996 | EP |
| 0882890 | Dec 1998 | EP |
| 1 454 935 | Aug 2004 | EP |
| 58-25326 | Feb 1983 | JP |
| 60-235847 | Nov 1985 | JP |
| 02-004826 | Jan 1990 | JP |
| 02 137 930 | May 1990 | JP |
| 08-283540 | Oct 1996 | JP |
| 09 287 571 | Nov 1997 | JP |
| 2004-514770 | May 2004 | JP |
| 2004-261045 | Sep 2004 | JP |
| 2004-269882 | Sep 2004 | JP |
| 2005269773 | Sep 2005 | JP |
| 2006353034 | Dec 2006 | JP |
| 2008211915 | Sep 2008 | JP |
| 2009046649 | Mar 2009 | JP |
| WO 9617170 | Jun 1996 | WO |
| WO 9620971 | Nov 1996 | WO |
| WO 9742412 | Nov 1997 | WO |
| WO 0028215 | May 2000 | WO |
| WO 0244240 | Jun 2002 | WO |
| WO 2004031581 | Apr 2004 | WO |
| WO 2004076859 | Sep 2004 | WO |
| WO 2005061014 | Jul 2005 | WO |
| WO 2005118008 | Dec 2005 | WO |
| WO 2006065884 | Jun 2006 | WO |
| WO 2008079440 | Jul 2008 | WO |
| WO 2009069086 | Apr 2009 | WO |
| Entry |
|---|
| Office Action issued Nov. 23, 2012 in U.S. Appl. No. 12/745,880 (26 pgs.). |
| “An Electrochemical Microactuator: Principle and First Results”, Neagu et al. Journal of Microelectromechanical Systems, vol. 5, No. 1. Mar. 1996 (7 pgs). |
| “ElectroActive Polymers—EAPs,” downloaded from http://www.azom.com on Dec. 16, 2013 (5 pgs). |
| “Epoxy-Based Electroactive Polymer Gels”, Yoshioka Y and Calvert P, Experimental Mechanics, vol. 42, No. 4, Dec. 2002, pp. 404-408 (5 pgs). |
| “Magnetic Driven Compression Cascade and Packaging”, IBM Technical Disclosure Bulletin, IBM Corp., col. 38, co. 1, Jan. 1995 (3 pgs). |
| “Micro-Dispensing Positive Displacement Pump”, Anonymous, Research Disclosure, Mason Publications, Hampshire GB, vol. 374, No. 4, Jun. 1995 (9 pgs). |
| “Structure and Mechanism of Two Types of Micro-Pump Using Polymer Gel”, Hattori et al., Micro Electro Mechanical Systems, 1992, MEMS 92, Proceedings. An Investigation of Micro Structures, Sensors, Actuators, Machines and Robot, IEEE Travemunde, Germany, Feb. 1992 (6 pgs). |
| Bar-Cohen, Y., “Electroactive polymers (EAP) actuators as artificial muscles: reality, potential and challenges,” SPIE Press, 2001, 671 pgs, (book description only, 4 pgs). |
| Canadian Official Action issued in Appln. No. 2,557,325, dated Feb. 8, 2011 (5 pgs). |
| Chinese Notification of ReExamination and English translation, Appln. or Pat. No. 200580048306.3; dated Aug. 22, 2014 (11 pgs). |
| Chinese Office Action (w/English translation) issued in corresponding application No. 200780032137.3, dated Mar. 12, 2013 (14 pgs). |
| Chinese Office Action and Translation dated Jul. 6, 2011 issued in Chinese Patent Appln. No. 200780032137.3 (7 pgs). |
| Chinese Office Action issued Jul. 1, 2014 with English translation, Appln. No. or Patent No. 201180007957.3 (17 pgs). |
| Chinese Office Action, Application/Patent No. 200780032137.3, dated Dec. 23, 2011 (6 pgs). |
| Chinese Official Action + translation dated Feb. 1, 2011 issued in Appln. No. 200780032137.3, (8 pgs). |
| Chinese Official Action dated Mar. 17, 2011, Appln. No. 200580048306.3 (5 pgs). |
| Chinese Official Action issued in corresponding Chinese Patent Appln. Serial No. 200580048306.3 dated Nov. 4, 2011 (5 pgs). |
| European Office Action dated Sep. 14, 2010, Appln. No. 07 872 242.8-2102, (6 pgs). |
| European Official Action issued in Appln. No. 04714231.0, dated May 11, 2011 (2 pgs). |
| European Official Action issued in Appln. No. 04714231.0-2315/1611353, dated Oct. 4, 2010 (4 pgs). |
| European Official Action, Apr. 6, 2011 issued in Appln. No. 07 872 242.8-2102 (4 pages). |
| European Official Action, Aug. 29, 2011 issued in Appln. No. 07 872 242.8-2102 (6 pages). |
| European Search Report dated Feb. 18, 2011 issued in corresponding Appln. No. 10014840.2-2315 (7 pgs). |
| European Search Report dated Jun. 8, 2009, Serial No. 07872242.8-2102 (7 pgs). |
| First Examination Report dated Dec. 31, 2013, Indian Patent Application No. 3011/CHENP/2007 (2 pgs). |
| Indian Examination Report; Indian Patent Application Serial No. 2371/CHENP/2005, dated Sep. 7, 2006 (2 pgs). |
| International Preliminary Report on Patentability issued in PCT/US10/48489 dated Mar. 13, 2012 (12 pgs). |
| International Search Report and Written Opinion issued in corresponding PCT Patent Appln. Serial No. PCT/US2012/057129 dated Apr. 1, 2014 ( 7 pgs). |
| International Search Report and Written Opinion of the International Search Authority issued in PCT/US09/34557, dated Apr. 13, 2009 (6 pgs). |
| Japanese Office Action with translation, Patent Appln. 2009-519642, dated Jul. 9, 2012 (9 pgs). |
| Office Action issued in related U.S. Appl. No. 10/786,718, dated Mar. 5, 2008 (41 pgs). |
| Office Action issued in related U.S. Appl. No. 10/786,718, dated Sep. 16, 2008 (8 pgs). |
| Office Action issued in related U.S. Appl. No. 10/786,718, dated Jan. 2, 2009 (9 pgs). |
| Office Action issued in related U.S. Appl. No. 10/786,718, dated Jul. 1, 2009 (7 pgs). |
| Office Action issued in related U.S. Appl. No. 10/786,718, dated Dec. 28, 2009 (6 pgs). |
| Office Action issued in related U.S. Appl. No. 10/786,718, dated May 5, 2010 (7 pgs). |
| Office Action issued in related U.S. Appl. No. 10/786,718, dated Sep. 15, 2010 (8 pgs). |
| Office Action issued in related U.S. Appl. No. 10/786,718, dated Nov. 23, 2010 (10 pgs). |
| Office Action issued in related U.S. Appl. No. 11/254,537, dated Sep. 17, 2007 (8 pgs). |
| Office Action issued in related U.S. Appl. No. 11/254,537, dated Mar. 4, 2008 (8 pgs). |
| Office Action issued in related U.S. Appl. No. 11/254,537, dated Jul. 21, 2008 (10 pgs). |
| Office Action issued in related U.S. Appl. No. 11/254,537, dated Dec. 15, 2008 (8 pgs). |
| Office Action issued in related U.S. Appl. No. 12/373,245, dated Feb. 2, 2011 (13 pgs). |
| Office Action issued in related U.S. Appl. No. 12/373,245, dated Jul. 22, 2011 (11 pgs). |
| Office Action issued in related U.S. Appl. No. 12/373,245, dated Jun. 30, 2014 (18 pgs). |
| Office Action issued in related U.S. Appl. No. 12/414,536, dated Nov. 29, 2010 (8 pgs). |
| Office Action issued in related U.S. Appl. No. 12/978,152, dated May 23, 2011 (9 pgs). |
| Office Action issued in related U.S. Appl. No. 13/018,024, dated Aug. 7, 2014 (17 pgs). |
| Office Action issued in related U.S. Appl. No. 13/093,648, dated Aug. 29, 2013 (5 pgs). |
| Office Action issued in related U.S. Appl. No. 13/424,172, dated Jun. 27, 2012 (14 pgs). |
| Office Action issued in related U.S. Appl. No. 13/424,172, dated Nov. 9, 2012 (6 pgs). |
| Office Action issued in related U.S. Appl. No. 14/071,371, dated Aug. 21, 2014 (16 pgs). |
| Office Action issued in related U.S. Appl. No. 12/745,880, dated Jun. 3, 2013 (8 pgs). |
| Official Action received in corresponding Chinese Application No. 200480010203.3, Sep. 14, 2007 (19 pgs). |
| Official Action received in corresponding Chinese Application No. 200480010203.3, Nov. 14, 2008 (5 pgs). |
| Official Action received in corresponding EPO Application. No. 04 714 231.0-2315, Nov. 13, 2008 (5 pgs). |
| Official Action, U.S. Appl. No. 11/721,800, dated Aug. 27, 2010 (13 pgs). |
| PCT International Preliminary Report on Patentability, dated Aug. 26, 2005, PCT/US04/005922 (11 pgs). |
| PCT International Search Report and Written Opinion, dated Oct. 22, 2004, PCT/US04/005922 (17 pgs). |
| PCT International Search Report and International Preliminary Report on Patentability, dated Oct. 25, 2006, PCT/US05/45210 (10 pgs). |
| PCT International Search Report and International Preliminary Report on Patentability, dated Jul. 7, 2008, PCT/US07/73188 (8 pgs). |
| PCT International Search Report and International Preliminary Report on Patentability, dated Feb. 19, 2009, PCT/US08/85421 (7 pgs). |
| PCT International Search Report and Written Opinion dated Mar. 28, 2011 PCT/US11/23375 (10 pgs). |
| PCT International Preliminary Report on Patentability issued in PCT/US2013/031062, dated Sep. 16, 2014 (9 pgs). |
| Search Report and Written Opinion received in Applicant's corresponding European Patent Application Serial No. 05854009.7, Nov. 11, 2009 (8 pgs). |
| Supplemental European Search Report issued in EP04714231, dated Jan. 25, 2007 (2 pgs). |
| Unsolicited letter from Dr. Elson Silva, dated Oct. 21, 2010 (5 pgs). |
| Yoshioka et al., “Electrically Driven Miniature Hydrogels as Muscle-Like Acuators”, 2001; Proceedings of SPIE vol. 4329, pp. 216-222 (7 pgs). |
| Office Action issued in related U.S. Appl. No. 14/071,371, dated Dec. 18, 2014 (11 pgs). |
| Japanese Office Action (with translation) issued in related application No. 2012-551386, dated Jan. 28, 2015 (9 pgs). |
| Office Action issued in related U.S. Appl. No. 13/395,627, dated Feb. 5, 2015 (7 pgs). |
| Chinese Board Decision, Appln. No. 200580048306.3, dated Dec. 26, 2014 (14 pgs). |
| Office Action issued in related U.S. Appl. No. 12/373,245, dated Feb. 9, 2015 (11 pgs). |
| Office Action issued in related U.S. Appl. No. 12/918,466, dated Jul. 11, 2013 (36 pgs). |
| India Hearing Notice in Reference of Application No. 3011/CHENP/2007, dated Feb. 5, 2015 (1 pg). |
| Office Action issued in U.S. Appl. No. 13/018,024, dated Feb. 24, 2015 (12 pgs). |
| Office Action issued in U.S. Appl. No. 13/424,172, dated Jun. 10, 2015 (14 pgs). |
| Office Action issued in U.S. Appl. No. 14/347,597, dated Jun. 3, 2015 (12 pgs). |
| Indian Office Action issued in application No. 137/CHENP/2009, dated Mar. 17, 2015 (2 pgs). |
| Office Action issued in U.S. Appl. No. 12/745,880, dated Jul. 22, 2015 (16 pgs). |
| Chinese Office Action issued in application No. 201180007957.3, dated May 22, 2015, with English translation (15 pgs). |
| Office Action issued in U.S. Appl. No. 13/018,024, dated Aug. 4, 2015 (10 pgs). |
| Number | Date | Country | |
|---|---|---|---|
| 20120191060 A1 | Jul 2012 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61241375 | Sep 2009 | US | |
| 61244884 | Sep 2009 | US | |
| 61267334 | Dec 2009 | US | |
| 61295247 | Jan 2010 | US |
